Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Mantle-Cell 1Carcinoma, Renal Cell 1

Interventions

Rituximab 117Cyclophosphamide 104fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Cytarabine 47Etoposide 44Mycophenolic Acid 41Filgrastim 40Whole-Body Irradiation 37Tacrolimus 36Melphalan 35Bortezomib 34Methotrexate 33Cyclosporine 33Busulfan 31Radiotherapy 30Vincristine 28Doxorubicin 27Dexamethasone 27Carmustine 25Antilymphocyte Serum 25Lenalidomide 23Bendamustine Hydrochloride 23ibrutinib 22Granulocyte Colony-Stimulating Factor 20obinutuzumab 18fludarabine 18acalabrutinib 18Prednisone 18venetoclax 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Mantle-Cell × MLN2238 × Clear all
NCT04047797 2025-04-20

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡